The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence
William H Gmeiner, Waldemar Debinski, Carol Milligan, David Caudell, Timothy S Pardee, William H Gmeiner, Waldemar Debinski, Carol Milligan, David Caudell, Timothy S Pardee
Abstract
F10 is a novel polymeric fluoropyrimidine drug candidate with strong anticancer activity in multiple preclinical models. F10 has strong potential for impacting cancer treatment because it displays high cytotoxicity toward proliferating malignant cells with minimal systemic toxicities thus providing an improved therapeutic window relative to traditional fluoropyrimidine drugs, such as 5-fluorouracil. F10 has a unique mechanism that involves dual targeting of thymidylate synthase and Top1. In this review, the authors provide an overview of the studies that revealed the novel aspects of F10's cytotoxic mechanism and summarize results obtained in preclinical models of acute myeloid leukemia, acute lymphocytic leukemia, glioblastoma and prostate cancer that demonstrate the strong potential of F10 to improve treatment outcomes.
Keywords: acute leukemia; cancer chemotherapy; fluoropyrimidine; glioblastoma; prostate cancer; thymineless death; topoisomerase.
Conflict of interest statement
Financial & competing interests disclosure The authors advise Salzburg Therapeutics, which is involved in commercialization of F10 for cancer treatment and are inventors on issued patents and pending patent applications filed by Wake Innovations. The authors are grateful for support from the Wake Forest Baptist Comprehensive Cancer Center P30 CA012197. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Figures
Source: PubMed